Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment
This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual target IDO & TDO inhibitors for modulation of the immunosuppressive tumor microenvironment as of December 2016. Selective and dual target novel indoleamine 2,3-dioxygenase (IDO) inhibitors and tryptophan 2,3-dioxygenase (TDO) inhibitors are being evaluated as single agents as well as in combination studies with other immune checkpoint modulators.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of IDO & TDO inhibitors for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of IDO & TDO inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual target IDO & TDO inhibitors for modulation of the immunosuppressive tumor microenvironment as of December 2016. Selective and dual target novel indoleamine 2,3-dioxygenase (IDO) inhibitors and tryptophan 2,3-dioxygenase (TDO) inhibitors are being evaluated as single agents as well as in combination studies with other immune checkpoint modulators.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of IDO & TDO inhibitors for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of IDO & TDO inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) IDO & TDO INHIBITORS
Epacadostat Studies – monotherapy & combinations
Indoximod Studies – monotherapy & combinations
Novel Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors
Dual IDO & TDO Inhibitors
2) CORPORATE IDO & TDO INHIBITOR PIPELINES
Epacadostat Studies – monotherapy & combinations
Indoximod Studies – monotherapy & combinations
Novel Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors
Dual IDO & TDO Inhibitors
2) CORPORATE IDO & TDO INHIBITOR PIPELINES